Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

Panelists discuss how the updated SEQUOIA Arm C data demonstrate that zanubrutinib monotherapy achieves a remarkable 72% ...

Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly ...

An expert discusses emerging real-world strategies for managing adverse effects of antibody-drug conjugates (ADCs) in ...

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

Panelists discuss how future directions in chronic lymphocytic leukemia (CLL) treatment include promising developments with Bruton tyrosine kinase (BTK) degraders, noncovalent BTK inhibitors, ...

Panelists discuss how measurable residual disease (MRD) testing should be used primarily for prognostic information rather than routine treatment decision-making, with current guidelines recommending ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...